Introduction
Haber-Weiss reactions, it has been suggested that DFO's protective influence could be caused by Fe chelation, leading to decreased OH production, and hence, less renal oxidant tissue stress ( 1, 2) . Thus, these results suggest that DFO could find clinical application for preventing MH-ARF.
Mannitol is another drug with proven efficacy against experimental (4-6), as well as clinical (7) (8) (9) heme protein nephrotoxicity. Like DFO, mannitol can also decrease OH levels, although it does so by OH scavenging, not by decreasing OH production. Furthermore, mannitol may protect against MH-ARF by its diuretic action, decreasing cast formation and possibly proximal tubular heme protein uptake (3, 4) . Indeed, a recent study from this laboratory suggests that mannitol's diuretic action could be primarily responsible for its in vivo protective influence (4) .
Given that mannitol and DFO can each mitigate experimental MH-ARF, but that neither agent is totally protective (e.g., [1] [2] [3] [4] , an important clinical question is whether their benefits are additive. In this regard, the following issues seem relevant: (a) Because mannitol and DFO may confer protection by different mechanisms (diuresis and Fe chelation, respectively), their beneficial effects may be additive or synergistic. Alternatively, if mannitol and DFO each act by decreasing OH levels, then combined therapy may be superfluous. (b) Although DFO is generally believed to decrease Fe-mediated OH production, it can also paradoxically accentuate it, presumably by accelerating Fe2" autoxidation (10, 11) . Under this circumstance, provision of an OH scavenger such as mannitol might negate this adverse DFO effect, thereby enhancing its cytoprotective influence. (c) Because diuretics can theoretically decrease intrarenal DFO accumulation caused by enhanced urinary washout, mannitol might negate DFO's protective influence. Alternatively, mannitol and DFO might work in concert to decrease the intrarenal Fe burden by exerting combined diuretic and chelation effects.
Given the above considerations, it is unclear whether mannitol and DFO have additive/synergistic or mutually exclusive protective effects against MH-ARF. Since this issue has not been previously tested, and because of its obvious clinical rele-vance, the goals of the present study were to: (a) determine whether DFO addition to mannitol therapy can improve upon the latter's protective influence in an in vivo model of MH-ARF; (b) test the hypothesis that excess catalytic Fe (i.e., nonprotein bound Fe capable of catalyzing free radical reactions) is, in fact, generated during MH-ARF; (c) assess whether this increased catalytic Fe activity causes excess intrarenal 'OH production; (d) determine whether mannitol and DFO decrease this catalytic Fe burden by enhancing its excretion and by chelation, respectively; (e) define whether mannitol and DFO confer direct and additive cytoprotection against proven proximal tubular oxidant insults (Fe and H202); and (f) ascertain whether such protection correlates with reductions in 'OH production (DFO) or with OH scavenging (mannitol). If so, these data, in concert, would support the hypothesis that mannitol and DFO exert additive protection in vivo because of overlapping antioxidant, cytoprotective effects.
Methods
In vivo experiments: effects ofDFO on mannitol-mediated protection against MH-ARF. Male Sprague Dawley rats 200-330 g (Harlan Sprague Dawley, Indianapolis IN), maintained under standard vivarium conditions with free food and water access were used for all experiments. On the morning of experimentation, they were anesthetized with pentobarbital (30-40 mg/kg i.p.), two jugular venous catheters (PE-50) were inserted, and then each rat was injected intramuscularly with 50% glycerol, 10 mg/kg (two equally divided doses into each hind limb). After glycerol injection, the rats were divided into two experimental groups: (a) in mannitol therapy/no DFO, 10 rats were infused with 1.25 ml of 25% mannitol per 100 g of body weight over 2 h, the first 1 ml being administered during 5 min at the start of the infusion; and (b) in mannitol plus DFO therapy, the rats received mannitol as noted above, with deferoxamine (Ciba-Geigy, Summit, NJ) being added to the mannitol infusion (total dose, 12 mg/ 100 g body wt). Urine was collected every 30 min 0-2 hr post-glycerol injection by external bladder compression. The volume of urine passed was determined and then an equal amount of 0.45% NaCl was infused intravenously over 5 min through the second jugular venous catheter to avoid volume depletion caused by the mannitol-stimulated diuresis. The 2-h urine samples were saved for catalytic Fe assay, as described below. Then the rats recovered from anesthesia, free food and water access being allowed. 24 h later, they were reanesthetized and killed by aortic puncture. The plasma was used for "blood" urea nitrogen (BUN) and plasma creatinine assay. The kidneys were resected and frontal sections were cut and fixed by immersion in 10% buffered formalin for subsequent histologic analysis, as described below. As points of reference for the above experiments, the severity of ARF induced by glycerol injection alone and DFO's independent effect on it were assessed. To these ends, 16 rats were anesthetized and injected with glycerol as noted above. Half received a 2-h DFO infusion (total dose, 12 mg/ 100 g body wt, dissolved in 1 ml of 5% dextrose and water, the first 0.25 ml being administered over 5 min immediately after glycerol injection). The other rats received a sham DFO infusion. As detailed above, all urine excreted 0-2 h after glycerol injection was collected and saved for catalytic Fe assay. To correct for possible differences in urine output, and hence, extracellular fluid volume, the amount of urine passed each 30 min was determined and an equal amount of 0.45% NaCl was injected intraperitoneally (< 0.7 ml per injection). The rats were allowed to recover from anesthesia and the severity of ARF was assessed 24 h later by determining BUN and plasma creatinine concentrations.
Plasma catalytic Fe concentrations during the initiation phase of MH-ARF. To assess whether plasma, as well as urinary catalytic Fe activity rises after glycerol injection, five rats were anesthetized, a carotid artery catheter was placed, and a 0.5-ml baseline blood sample was obtained. Then the rats were injected with glycerol and repeat 0.5-ml blood samples were obtained 15 min and 2 h later. These samples (0, 15, and 120 min) were saved for catalytic Fe assay (see below). To determine whether DFO chelates a plasma catalytic Fe increment, five additional rats were treated as above, except they were subjected to the DFO/5% dextrose infusion (as previously discussed).
The following experiment assessed whether plasma catalytic Fe is cleared by the kidney, thereby contributing to urinary catalytic Fe activity. Three rats underwent bilateral nephrectomy through a midline abdominal incision and then they were injected with glycerol, as noted above. 2 h later, a plasma sample was obtained and analyzed for catalytic Fe. Renal catalytic Fe clearance was indirectly gauged by determining whether these 2-h plasma catalytic Fe concentrations were significantly higher than those observed in three additional rats subjected to sham bilateral nephrectomy and glycerol injection.
Intrarenal OH radical production during the initiation phase of MH-ARF. To assess whether plasma/urinary catalytic Fe increments cause excess intrarenal 'OH generation, the salicylate trap method was used (11) (12) (13) (14) (15) (16) . In brief, Na salicylate serves as a stable 'OH trap, 2,3-and 2,5-dihydroxybenzoic acids (DHBA) being byproducts ofthis reaction. Thus, increments in DHBA concentrations serve as indices of OH generation. Alternatively, decrements in DHBA indicate decreased OH production or OH scavenging. Supporting the utility of this technique are that (a) increased DHBA production occurs with OH generating systems (11) (12) (13) (14) (15) (16) ; and (b) selected antioxidants (oxypurinol, dimethylthiourea, DFO) decrease DHBA production both in vivo and in vitro ( 1 1, 16, and unpublished observations by this laboratory). Eight rats were anesthetized, they were injected with Na salicylate, 100 mg/kg i.p., and then half were injected with glycerol, the remaining half serving as controls. 2 h later, the kidneys were resected, cooled to 4°C, the cortical/outer medullary regions resected, homogenized, and extracted in 4 vol of 10% trichloracetic acid, and then subjected to high performance liquid chromatography (System B) (16), the elutions being conducted with citrate/acetate buffer (pH 2.3/ 34% methanol). The 2,3-, 2,5-DHBA, and salicylate concentrations were quantified by electrochemical detection ( 15, 16) (sensitivity, 0.1 nmol / ml). The DHBA results were expressed in two ways: (a) as absolute concentrations per gram tissue dry wt; and (b) as absolute concentrations divided by the salicylate concentration (thereby factoring for differences in DHBA precursor accumulation within each kidney) ( 16) .
In vitro experiments: effects ofDFO and mannitol therapy on Femediated proximal tubular segment cytotoxicity, Fe in molar excess. The following experiment was performed to assess whether mannitol and DFO confer direct additive/synergistic protection against Fe-mediated proximal tubular cell injury and whether such protection correlates with decrements in OH levels. To this end, proximal tubular segments (PTS) were harvested from normal rats by a previously described technique ( 17) . In brief, the rats were subjected to retrograde aortic perfusion with a balanced salt solution to render the kidneys bloodless ( 17), they were resected, and the cortical tissues were isolated and minced with a razor blade at 4°C. The resulting tissues were digested with a collagenase containing buffer to which 1 mM DFO was added to chelate any free Fe generated during the mincing and digestion process ( 16) . Viable PTS were recovered using a 31% Percoll gradient ( 17) , and then they were washed 5 x to remove any remaining collagenase and DFO. The PTS were suspended to a concentration of 2-4 mg PTS protein/ml in a buffer consisting of NaCl 100 mM, KCI 2.1 mM, NaHCO3 25 mM, KH2PO4 2.4 DFO in molar excess. In this experiment, the effects ofDFO±mannitol on in vitro Fe toxicity was assessed when the DFO was present in slight molar excess of the total amount of Fe added (6 mM DFO and 5 mM Fe). In all other respects, this experiment was repeated exactly as described above (n = 4 PTS preparations).
Effect ofthe Fe/DFO molar ratio on DFO-mediated cytoprotection and OH generation. In the above in vitro experiments, the different Fe/ DFO molar ratios employed (5:4 or 5:6) produced different degrees of LDH release and OH (DHBA) generation. The present experiment more fully explored these relationships. Three separate PTS preparations were each divided into seven equal aliquots as follows: (a) 5 mM Fe/no DFO addition; (b) 5 . After a l-h 37°C incubation, BSA's carbonyl content, an index ofprotein oxidation ( 18, 19) was assessed by the method of Stadtman ( 19). To determine whether FeSO4/ DFO-mediated protein oxidation was 'OH dependent, aliquot No. 4 was repeated 3x in the presence of 100 mM mannitol.
Hl2O2 mediated PTS injuiry: DFO and mannitol effects on LDH release and OH generation. In the above described PTS experiments, Fe was the imposed oxidant challenge. However, data from Guidet and Shah (20) indicate that in in vivo MH-ARF (glycerol model), excess H202 generation occurs. Thus, the present experiment evaluated (a) whether H202-mediated cytotoxicity can be blunted with mannitol and DFO therapy; (b) whether H202 addition leads to excess PTS OH generation (e.g., via the Haber Weiss reaction); and (c) whether DFO and mannitol influence these processes. To these ends, the PTS preparation procedure was modified in order to eliminate DFO from the PTS isolation process. This was done because it is theoretically possible that DFO, when added to the collagenase buffer, could have rendered the PTS Fe-deficient, thereby inhibiting the ability of H202 to generate 'OH via the Haber Weiss reaction. Thus, PTS were prepared with two modifications: (a) DFO was not added to the collagenase digestion buffer; and (b) the kidneys were not perfused in vivo; thus, the mincing/digestion process occurred in the presence of intrarenal blood, leaving transferrin to bind free Fe generated during collagenase digestion. Five PTS preparations were so isolated, each one being divided into six aliquots: (a) control incubation (no addition); (b) 15 mM H202 addition (shown in preliminary experiments to be the minimal dose necessary to induce consistent cytotoxicity (LDH release); (c) 15 mM H202 + 4 mM DFO; (d) 15 mM H202 + 100 mM mannitol; (e) 15 mM H202 + 4 mM DFO + 100 mM mannitol; and (f) 15 ( 11) . After 45 min, the percentage of LDH release and DHBA concentrations were determined. To prove that 25 mM DMTU had no direct cytotoxic effect, potentially masking a beneficial action against H202, six additional PTS aliquots had LDH release determined in the presence or absence of 25 mM DMTU (n = 3 each).
Influence ofH202 addition on PTS catalytic Fe activity. The following experiment assessed whether H202 increases PTS catalytic Fe activity, suggesting a possible link between H202 and Fe-mediated PTS toxicity (other than 'OH production via the Haber Weiss reaction). Four PTS preparations, isolated without DFO addition, were each divided into four aliquots: two were incubated with 15 mM H202, while two were incubated with only an equal amount of buffer addition. After 20 min (a time before substantial cell killing occurs), the percentage of LDH release was determined, and each PTS suspension was assayed for catalytic Fe activity, as described below.
Bleomycin assay for catalytic Fe activity. Catalytic Fe was measured in the above experiments by a modification of the bleomycin method of Gutteridge and Hou (21 ) . All measurements were made in duplicate. The reagents, unless otherwise stated, were from Sigma Chemical Co. (St. Louis, MO) and were dissolved in deionized water ([ DW ], Milli-Q) pretreated with Chelex-100 to remove contaminating Fe. Reagent solutions were subsequently treated with Chelex-100 and stored in plastic containers. Plastic incubation tubes contained, in order: 0.5 ml of 1 mg/ml DNA (type 1, calf thymus); 0.1 ml of 0.1 U/ml bleomycin sulfate; 0.1 ml of 50 mM MgCl2; 0.1 ml of 1.0 M imidazole, pH 7.3; 0.1 ml of sample; and 0.1 ml of 8 mM ascorbic acid (ACS reagent grade). Samples were incubated by shaking for 2 h, at 37°C. The reactions were stopped with 0.1 ml of 1.0 M EDTA addition (Na salt, pH 7.3) and developed with 1.0 ml of 1% (wt/vol) thiobarbituric acid in 50 mM NaOH and 1.0 ml of 25% (vol/vol) HCI. The samples were heated for 10 min at 100°C and then cooled. 1.5 ml of n-butanol was added and mixed, and the mixture was centrifuged for 15 min at 1,100 g, room temperature. A532 of the supernatant was measured vs n-butanol. Catalytic Fe concentrations were calculated by interpolation on a standard curve generated with FeCI3 standards (0-10 ,M) in Chelex-treated DW. Plasma and urine samples were diluted 
Results
In vivo experiments: severity ofMH-ARF (Fig. 1) . Mannitol infusion in the absence of DFO caused a marked diuresis, averaging 8.3±1.4 ml over the 0-2-h post-glycerol injection period.
The addition of DFO to the mannitol infusion did not significantly affect this urine flow rate (7.0±1.2 ml/2 h). By unpaired Student's t test analysis, the DFO + mannitol treated rats had significantly better renal function than the mannitol only group, as assessed by both the 24-h BUN (P < 0.01 ) and plasma creatinine concentrations (P < 0.005; see Fig. 1 ). The degree of heme pigment cast formation 24 h post-glycerol injection was mild in both groups (< 10% of distal tubular segments involved), and the extent of this finding did not appear to be affected by the DFO therapy. However, the extent of proximal tubular necrosis was significantly less in the mannitol + DFO vs the mannitol only group (score 1.3±0.15 vs 2.6±0.16; P <0.01).
DFO therapy in the absence of mannitol infusion appeared to decrease the degree of azotemia, compared to the untreated glycerol group, but the BUN and creatinine values for these two groups did not statistically differ (Fig. 1 ) fashion, except for using a 7 ml/kg rather than a 10 ml/kg glycerol challenge, a lack of excess 2,3-and 2,5-DHBA generation was also apparent, compared to controls.) PTS experiments: 5 mM Fe/4 mM DFO + mannitol addition (Fig. 2) . The percentage of LDH released after 15 min of rewarming and after 45 min of incubation under control conditions were 6±1% and 1 1±0%, respectively (typical for all of the PTS experiments). Neither mannitol nor DFO, either alone or in combination, altered LDH release in the absence of the Fe challenge (Fig. 2 C) . 5 mM Fe addition caused marked cytotoxicity (39±1% LDH release), a result which, surprisingly, was not significantly affected by 4 mM DFO or mannitol addition, either alone or in combination (Fig. 2 D) .
The PTS groups incubated in the absence of the exogenous Fe challenge had DHBA concentrations ranging from 1.4-2.7 nmol DHBA/ml PTS buffer (means presented in Fig. 2 A) . nmol/ml) (Fig. 2 B) (Fig. 3) . As in the above experiments, neither mannitol nor DFO addition altered LDH release in the absence of exogenous Fe (Fig. 3 C) . Once again, Fe caused 39±2% LDH release. However, in contrast to 4 mM DFO, 6 mM DFO induced significant protection, decreasing the percentage ofLDH released to 24±3% (P < 0.05; Fig. 3 D) . Mannitol exerted no protective influence, either in the presence or absence of concomitant DFO therapy.
As noted above, neither mannitol, DFO, nor Fe, when added by themselves to PTS, caused a significant change in total DHBA concentrations (Fig. 3 A, B) . However, Fe + 6 mM DFO more than doubled the total DHBA levels (P < 0.01; Fig. 3 B) , again because of increments in both 2,3-and 2,5-DHBA. Mannitol significantly lowered these DHBA concentrations either when it was coincubated with Fe (mannitol + Fe, 1 .4+0.1; Fe alone, 2.6±0.1 nmol/ml; P < 0.01 ), or in the presence ofFe + DFO (Fe + DFO, 5.3±0.3; Fe + DFO + mannitol, 3.1+0.3 nmol/ml; P < 0.01). However, despite these reductions, no cytoprotection resulted, as noted above.
PTS experiments: 5 mM Fe and 0-8 mM DFO, effects on OHproduction and cytotoxicity (Fig. 4) . As depicted in Fig. 4 , there was a striking inverse correlation between the amount of DFO added to the 5 mM Fe challenge and the extent of LDH released (2, 4, 6, and 8 mM DFO 38%, 31%, 20%, and 12% These results were similar to those found in the Fig. 2 (Fig.  4, top) . BSA oxidation (Fig. 5) . FeSO4, FeCl3, and H202 each induced a modest increase in the BSA carbonyl content (> 95% confidence band for BSA alone; see (control values, 1.1 nmol/ml; H202, 0.8 nmol/ml; P < 0.05, but NS after Bonferroni correction). No other significant differences in DHBA concentrations were apparent in these H202 experiments.
After 20 min of control incubation, the Fe concentrations in the PTS suspension were 2.08±0.19 ,uM. The paired PTS aliquots incubated for 20 min with H202 developed higher Fe concentrations in every instance (3.39±0.30 ,uM; P < 0.003). Thus, H202 addition raised the PTS catalytic Fe content by 63%. The percentage of LDH released in these 20 min experiments were: controls, 14+1%; H202, 20±1%, respectively (P < 0.005). Figure 5 . The shaded area represents the 95% confidence band for BSA carbonyl content in the absence of additions. FeSO4 (Fe2"), FeCl3 (Fe3"), and H202 each induced small, but significant, carbonyl content increments (above 95% confidence band), whereas DFO alone had no effect. DFO had no independent effect on BSA carbonyl content. However, in the presence ofFeSO4, DFO caused a marked carbonyl content increment which could be totally blocked by mannitol addition. In contrast, FeCl3-mediated BSA oxidation was decreased, not increased, by DFO addition. DFO had no significant effect on the BSA oxidation induced by H202 addition.
Discussion
PTS experiments: H/02 challenge and evaluation ofprotective agents (Fig. 6) . After 45 min ofincubation, H202 induced significant cytotoxicity (30±2% LDH release vs 13±1% for control incubation; P < 0.01 ) (Fig. 6) . Addition of DFO completely abolished this H202-mediated damage (12±1% LDH release; NS vs controls). However, neither mannitol nor DMTU addition conferred cytoprotection (27±2% and 33±1% LDH release, respectively; NS vs H202 alone). DMTU in the absence of H202 had no impact on PTS viability (DMTU and control incubation, each 13±1% LDH release). The addition of H202 did not cause an increase in either 2,3-or 2,5-DHBA generation: rather, H202 tended to lower the total DHBA levels Figure 6 . Percentage of LDH release and DHBA concentrations after 45 min of 15 mM H202 exposure. H202 caused significant cytotoxicity (increased LDH release vs non-H202-exposed controls 0; P < 0.01 ). This toxicity occurred without a significant increase in DHBA concentrations. DFO conferred complete protection against H202 toxicity without significantly altering DHBA production. Neither mannitol nor DMTU conferred cytoprotection.
Mannitol is generally considered a mainstay for prophylaxis of MH-ARF. However, in a recent study, this laboratory found that when mannitol is used in the glycerol ARF model, its protective influence is incomplete, mitigating azotemia and heme protein cast formation, but not the extent of proximal tubular necrosis (4). In part, mannitol's inability to confer more complete functional and cellular protection may relate to the fact that during myohemoglobinuria, an active mannitol diuresis exacerbates tubular cell ATP depletion, probably because of an abrupt increase in GFR, and hence, in tubular metabolic work (4) . Because of these therapeutic limitations, the present study has sought to determine whether DFO addition can improve upon mannitol's overall protective effects.
As depicted in Fig. 1 , when DFO was added to the mannitol infusion, the extent of azotemia was almost halved, indicating an approximate doubling of GFR. In addition, DFO was able to decrease the extent ofproximal tubular necrosis; thus, unlike mannitol (4) , it confers a cytoprotective effect. A pertinent question is whether DFO yields this additive protection by further stimulating a diuresis, and hence, heme protein excretion during the initiation phase ofthe renal injury (e.g., 0-2 h postglycerol injection). This possibility is suggested by the fact that DFO doubled the 0-2-h urinary output in the absence of mannitol infusion. However, this hypothesis seems untenable for two reasons: (a) under conditions ofcombined DFO + mannitol infusion, the urine output was, ifanything, slightly lower in the combined therapy group, compared to mannitol treatment alone; and (b) in neither the mannitol nor the combined treatment group did the degree of protection correlate with the 0-2 h urinary outputs (e.g., BUN, creatinine vs urine output, r = -0.1 to +0.1; range of urine outputs, 2-16 ml/2 h). This latter observation indicates that although a diuresis confers protection, there is a maximal degree of benefit that can be achieved, so that further stimulation of urine output does not confer incremental benefits. The present in vivo experiments also serve to contrast relative degrees of protection afforded by mannitol vs DFO therapy. As used, mannitol alone (but not DFO alone) caused statistically significant improvements in renal function. Thus, these results suggest that were DFO to undergo future clinical trials for prevention of MH-ARF, it should not be tested as a substitute for mannitol, but rather, as an adjunctive therapy.
Having defined DFO's protective potential in the above experiments, the second goal ofthis study was Because DFO and mannitol can potentially influence MH-ARF by intravascular/intraluminal, as well as by direct cellular effects, the influence of DFO±mannitol therapy on direct Fe-mediated PTS cytotoxicity was assessed. Because previous work from this laboratory has indicated that 1-2 mM Fe is needed to induce cytotoxicity in this system ( 11) , and because additive/synergistic protection was sought, an even larger (5 mM) Fe challenge was chosen for these experiments. In light of the above in vivo data indicating that ,uM, not mM, Fe concentrations are present during myohemoglobinuria, a compelling question is whether sufficient catalytic Fe is generated in vivo to induce direct proximal tubular cytotoxicity, or whether the in vivo catalytic Fe activity merely represents an epiphenomenon. However, because the intracellular Fe concentrations and sites of accumulation which occur in vivo and in vitro are unknown, this remains an important but unanswered question. Nevertheless, the present in vitro studies can provide some insights as to whether mannitol and DFO exert additive protective effects against a catalytic Fe challenge, and whether that protection correlates with decreased *OH production or activity.
To initially address these issues, PTS were incubated with 5 mM Fe±a molar deficit of DFO (4 mM), so that incomplete cytoprotection would result. Thus, if mannitol and DFO were to confer additive benefits, they should have been apparent in this experiment. Surprisingly, 4 mM DFO conferred no protection whatsoever, indicating that it must be present in at least molar equivalence to Fe to have a beneficial impact. Similarly, mannitol exerted no protective influence (Fig. 2) , either in the presence or absence of DFO therapy. To help substantiate these findings, experiments were conducted with DFO in slight molar excess (6 mM) to the Fe challenge (Fig. 3) . Under these circumstances, DFO ( 11) .
To further explore this possibility, the effects of different Fe/DFO ratios on 'OH production and Fe-mediated cytotoxicity were assessed. As depicted in Fig. 4 (4, 30) , also support this view. Thus, the critical pathways by which heme Fe/heme proteins induce tubular injury remain to be defined.
In conclusion, the present study indicates that (a) DFO However, that mannitol does not (i) directly limit Fe/H202-mediated in vitro PTS injury; (ii) that it has limited access to intracellular locations; and (iii) that its in vivo protective influence correlates with decreased cast formation, not decreased cell necrosis (4) , all suggest that its in vivo benefit is derived from a diuretic, not an OH scavenging effect. (f) H202-mediated PTS toxicity appears to be Fe-(but not OH-) dependent, since (i) H202 addition caused no apparent OH generation; (ii) OH scavengers (mannitol, DMTU) conferred no benefit; and (iii) H202 liberated catalytic Fe, the chelation of which caused complete protection. Thus, an enhancement of the intracellular catalytic Fe burden, rather than 0OH-mediated oxidant stress, may be the more critical determinant of H202-mediated tubular injury. However, the mechanism(s) by which Fe exerts this toxicity remains unknown.
